Royal Bank of Canada’s Adamas Pharmaceuticals ADMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-200
Closed -$1K 8257
2021
Q3
$1K Hold
200
﹤0.01% 7577
2021
Q2
$1K Hold
200
﹤0.01% 7421
2021
Q1
$1K Sell
200
-42
-17% -$219 ﹤0.01% 7365
2020
Q4
$1K Sell
242
-169
-41% -$723 ﹤0.01% 7015
2020
Q3
$2K Sell
411
-1,453
-78% -$5.62K ﹤0.01% 6366
2020
Q2
$5K Buy
1,864
+1,567
+528% +$4.61K ﹤0.01% 6072
2020
Q1
$1K Sell
297
-2,498
-89% -$11.2K ﹤0.01% 6565
2019
Q4
$11K Sell
2,795
-5,204
-65% -$24.9K ﹤0.01% 6127
2019
Q3
$41K Buy
7,999
+381
+5% +$2.35K ﹤0.01% 5211
2019
Q2
$48K Buy
7,618
+18
+0.2% +$104 ﹤0.01% 5299
2019
Q1
$54K Hold
7,600
﹤0.01% 5122
2018
Q4
$65K Buy
7,600
+4,408
+138% +$57.3K ﹤0.01% 4963
2018
Q3
$64K Buy
3,192
+471
+17% +$11.1K ﹤0.01% 5111
2018
Q2
$71K Buy
2,721
+221
+9% +$6.12K ﹤0.01% 4998
2018
Q1
$60K Sell
2,500
-77
-3% -$2.43K ﹤0.01% 4974
2017
Q4
$88K Sell
2,577
-1,237
-32% -$34.5K ﹤0.01% 4890
2017
Q3
$81K Sell
3,814
-6,308
-62% -$116K ﹤0.01% 5151
2017
Q2
$177K Sell
10,122
-555
-5% -$9.18K ﹤0.01% 4436
2017
Q1
$187K Buy
10,677
+9,665
+955% +$165K ﹤0.01% 4371
2016
Q4
$17K Buy
+1,012
New +$15.7K ﹤0.01% 5864
2016
Q1
Sell
-13
Closed 6771
2015
Q4
$0 Sell
13
-441
-97% -$7.42K ﹤0.01% 6918
2015
Q3
$8K Sell
454
-410
-47% -$9.33K ﹤0.01% 6004
2015
Q2
$23K Buy
+864
New +$16.8K ﹤0.01% 5632
2015
Q1
Sell
-13
Closed 6498
2014
Q4
$0 Buy
+13
New +$197 ﹤0.01% 6360

Royal Bank of Canada's ADMS Position: Q4 2021 in Review

Royal Bank of Canada sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 200 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in ADMS in Q4 2014 and held it in 24 quarters. The position peaked at $187K in Q1 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

  • Royal Bank of Canada reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 200 Adamas Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Royal Bank of Canada first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 24 quarters.
  • Royal Bank of Canada's Adamas Pharmaceuticals position peaked at $187K in Q1 2017.
  • 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Royal Bank of Canada's 13F filing for Q4 2021, filed 14 Feb 2022.